DDP-4抑制剂联合阿卡波糖治疗2型糖尿病患者的效果

Effects of DDP-4 inhibitor combined with Acarbose on type 2 diabetes

目的:观察二肽基肽酶Ⅳ(DDP-4)抑制剂联合阿卡波糖治疗2型糖尿病患者的效果。方法:选取2019年9月至2020年9月该院收治的120例糖尿病患者进行前瞻性研究,按照随机数字表法将其分为对照组与观察组各60例。对照组采用阿卡波糖治疗,观察组在对照组基础上联合DDP-4抑制剂治疗,比较两组治疗前后血糖指标[空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)]水平、胰岛功能指标[胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)]水平、血脂指标[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)]水平和不良反应发生率。结果:治疗后,两组FBG、2hPG和HbA1c水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组HOMA-IR水平均低于治疗前,且观察组低于对照组,两组HOMA-β水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组TC、TG和LDL-C水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:DDP-4抑制剂联合阿卡波糖治疗2型糖尿病患者可降低血糖指标和血脂指标水平,改善胰岛功能指标水平,效果优于单纯阿卡波糖治疗。

Objective: To observe effects of DDP-4 inhibitor combined with Acarbose on type 2 diabetes. Methods: A prospective study was conducted on 120 diabetic patients admitted to the hospital from September 2019 to September 2020. They were divided into control group and observation group according to the random number table method, 60 cases in each. The control group was treated with Acarbose, while the observation group was treated with DDP-4 inhibitor on the basis of that of the control group. The levels of blood glucose indexes [fasting blood glucose(FBG), 2 h postprandial blood glucose(2 hPG), glycosylated hemoglobin(HbA1c)], the islet function index levels [insulin resistance index(HOMA-IR), islet β cell function index(HOMA-β)], the blood lipid index levels [total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C)], and the incidence of adverse reactions were compared between the two groups before and after the treatment. Results: After the treatment, the levels of FBG, 2hPG and HbA1c in the two groups were lower than those before the treatment, those in the observation group were lower than those in the control group, and the differences were statistically significant(P<0.05). The HOMA-IR levels of the two groups were lower than those before the treatment, and that in the observation group was lower than that in the control group;the HOMA-β levels of the two groups were higher than those before the treatment, and that in the observation group was higher than that in the control group;and the differences were statistically significant(P<0.05). The levels of TC, TG and LDL-C in the two groups were lower than those before the treatment, those in the observation group were lower than those in the control group, and the differences were statistically significant(P<0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: DDP-4 inhibitor combined with Acarbose in the treatment of the patients with type 2 diabetes can reduce the levels of blood glucose indexes and blood lipid indexes, and improve the levels of islet function indexes. Moreover, it is superior to single Acarbose treatment.